English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
GOI funds Epygen Biotech to make affordable COVID-19 vaccine for less than Rs. 150 against old and new variants
Epygen Biotech, an Indian Biopharmaceutical company engaged in research and manufacturing therapeutic proteins, has received funding from the Department of Biotechnology, Government of India to initiate the Phase I and Phase II trials of an indigenous affordable Receptor Binding Domain (RBD based vaccine) against present and future SARS-CoV–2 variants. With an anticipated price point of […]
Epygen Biotech Gets Funding From Govt For New Affordable Covid Vaccine
The company said it has received funding to initiate the Phase I and Phase II trials of an indigenous affordable Receptor-Binding Domain (RBD) based vaccine against the present and future SARS-CoV–2 variants. Epygen Biotech on Monday said it has received a funding of Rs 24 crore from the Department of Biotechnology to initiate trials for […]
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigen Funding earmarked to support Phase 1 and 2 clinical trials of Epygen’s COVID-19 vaccine candidate Dyadic’s C1 protein production platform will serve as foundation for Epygen’s initial low-cost commercial COVID-19 vaccine Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology […]
Epygen Biotech and Dyadic advance low-cost COVID-19 vaccine candidate
Dyadic licensee, Epygen Biotech, has received funding from the Government of India to advance a low-cost COVID-19 vaccine through Phase 1 and 2 clinical trials in India, using Dyadic’s C1 protein production platform. The companies aim to initially produce 100 million doses a year, with a price point of around $2 per dose. The vaccine […]
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigen Funding earmarked to support Phase 1 and 2 clinical trials of Epygen’s COVID-19 vaccine candidate Dyadic’s C1 protein production platform will serve as foundation for Epygen’s initial low-cost commercial COVID-19 vaccine JUPITER, Fla., April 13, 2022 […]
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigen Funding earmarked to support Phase 1 and 2 clinical trials of Epygen’s COVID-19 vaccine candidate Dyadic’s […]
DBT-BACKED EPYGEN TO START TRIALS ON COVID VACCINE BELOW ₹150 A SHOT
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform Indian biopharma company to initiate Phase-I and Phase-II trials, plans fundraise of Rs 200 crore of funding for third phase of trials Epygen Biotech, an Indian biopharmaceutical company engaged in research and manufacturing therapeutic proteins, […]